These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35688598)

  • 1. Therapy of genomic unstable solid tumours (WHO grade 3/4）in clinical stage III/IV using individualised neoantigen tumour peptides-INP trial (individualised neoantigen tumour peptides immunotherapy): study protocol for an open-label, non-randomised, prospective, single-arm trial.
    Wang L; Tang J; Chen X; Zhao J; Tang W; Liao B; Nian W
    BMJ Open; 2022 Jun; 12(6):e055742. PubMed ID: 35688598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours.
    Wang S; Huang HY; Wu D; Fang H; Ying J; Bai Y; Yu Y; Fang Y; Jiang N; Sun C; Yu A; Fan Q; Xing S; Ni Y; Zhang W; Wu C; Ji X; Wang H; Guo Y; Tang Q; Wang Y; Tang Y; Li N
    BMJ Open; 2021 Jun; 11(6):e044543. PubMed ID: 34083331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group.
    De Mattos-Arruda L; Vazquez M; Finotello F; Lepore R; Porta E; Hundal J; Amengual-Rigo P; Ng CKY; Valencia A; Carrillo J; Chan TA; Guallar V; McGranahan N; Blanco J; Griffith M
    Ann Oncol; 2020 Aug; 31(8):978-990. PubMed ID: 32610166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.
    Turajlic S; Litchfield K; Xu H; Rosenthal R; McGranahan N; Reading JL; Wong YNS; Rowan A; Kanu N; Al Bakir M; Chambers T; Salgado R; Savas P; Loi S; Birkbak NJ; Sansregret L; Gore M; Larkin J; Quezada SA; Swanton C
    Lancet Oncol; 2017 Aug; 18(8):1009-1021. PubMed ID: 28694034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the efficacy and safety of a precise thymalfasin-regulated PRaG regimen for advanced refractory solid tumours: protocol for the open-label, prospective, multicentre study (PRaG5.0 study).
    Kong Y; Chen R; Xu M; Zhang J; Chen G; Hong Z; Zhang H; Dai X; Ma Y; Zhao X; Peng Y; Zhang C; Xing P; Zhang L
    BMJ Open; 2024 Mar; 14(3):e075642. PubMed ID: 38458816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial.
    Okumura S; Ishihara M; Kiyota N; Yakushijin K; Takada K; Kobayashi S; Ikeda H; Endo M; Kato K; Kitano S; Matsumine A; Nagata Y; Kageyama S; Shiraishi T; Yamada T; Horibe K; Takesako K; Miwa H; Watanabe T; Miyahara Y; Shiku H
    BMJ Open; 2022 Nov; 12(11):e065109. PubMed ID: 36375974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report.
    Zeng Y; Zhang W; Li Z; Zheng Y; Wang Y; Chen G; Qiu L; Ke K; Su X; Cai Z; Liu J; Liu X
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of shared neoantigens in esophageal carcinoma by the combination of comprehensive analysis of genomic data and in silico neoantigen prediction.
    Yuan Y; Chen C; Liu S; Xiong H; Huang Y; Zhang X; Zhang X; Li B
    Cell Immunol; 2022 Jul; 377():104537. PubMed ID: 35636066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Pan-cancer Clinical Study of Personalized Neoantigen Vaccine Monotherapy in Treating Patients with Various Types of Advanced Solid Tumors.
    Fang Y; Mo F; Shou J; Wang H; Luo K; Zhang S; Han N; Li H; Ye S; Zhou Z; Chen R; Chen L; Liu L; Wang H; Pan H; Chen S
    Clin Cancer Res; 2020 Sep; 26(17):4511-4520. PubMed ID: 32439700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
    Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
    Marabelle A; Fakih M; Lopez J; Shah M; Shapira-Frommer R; Nakagawa K; Chung HC; Kindler HL; Lopez-Martin JA; Miller WH; Italiano A; Kao S; Piha-Paul SA; Delord JP; McWilliams RR; Fabrizio DA; Aurora-Garg D; Xu L; Jin F; Norwood K; Bang YJ
    Lancet Oncol; 2020 Oct; 21(10):1353-1365. PubMed ID: 32919526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.
    Balachandran VP; Łuksza M; Zhao JN; Makarov V; Moral JA; Remark R; Herbst B; Askan G; Bhanot U; Senbabaoglu Y; Wells DK; Cary CIO; Grbovic-Huezo O; Attiyeh M; Medina B; Zhang J; Loo J; Saglimbeni J; Abu-Akeel M; Zappasodi R; Riaz N; Smoragiewicz M; Kelley ZL; Basturk O; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; Gönen M; Levine AJ; Allen PJ; Fearon DT; Merad M; Gnjatic S; Iacobuzio-Donahue CA; Wolchok JD; DeMatteo RP; Chan TA; Greenbaum BD; Merghoub T; Leach SD
    Nature; 2017 Nov; 551(7681):512-516. PubMed ID: 29132146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.
    Berger F; Marce M; Delaloge S; Hardy-Bessard AC; Bachelot T; Bièche I; Pradines A; De La Motte Rouge T; Canon JL; André F; Arnould L; Clatot F; Lemonnier J; Marques S; Bidard FC;
    BMJ Open; 2022 Mar; 12(3):e055821. PubMed ID: 35241469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
    Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
    Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer.
    Ding Z; Li Q; Zhang R; Xie L; Shu Y; Gao S; Wang P; Su X; Qin Y; Wang Y; Fang J; Zhu Z; Xia X; Wei G; Wang H; Qian H; Guo X; Gao Z; Wang Y; Wei Y; Xu Q; Xu H; Yang L
    Signal Transduct Target Ther; 2021 Jan; 6(1):26. PubMed ID: 33473101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalised neoantigen-based therapy in colorectal cancer.
    Zhu YJ; Li X; Chen TT; Wang JX; Zhou YX; Mu XL; Du Y; Wang JL; Tang J; Liu JY
    Clin Transl Med; 2023 Nov; 13(11):e1461. PubMed ID: 37921274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction.
    Müller M; Huber F; Arnaud M; Kraemer AI; Altimiras ER; Michaux J; Taillandier-Coindard M; Chiffelle J; Murgues B; Gehret T; Auger A; Stevenson BJ; Coukos G; Harari A; Bassani-Sternberg M
    Immunity; 2023 Nov; 56(11):2650-2663.e6. PubMed ID: 37816353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial.
    Golden EB; Chhabra A; Chachoua A; Adams S; Donach M; Fenton-Kerimian M; Friedman K; Ponzo F; Babb JS; Goldberg J; Demaria S; Formenti SC
    Lancet Oncol; 2015 Jul; 16(7):795-803. PubMed ID: 26095785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.